Biotech

Pharma

Four of the world’s largest drug companies are teaming with Verily. Here is what they get

By Matthew Herper

Health Tech

Singapore digital health startup raises $35 million, plans headquarters move to Boston

By Larry Edelman — Boston Globe

Biotech

Biocryst clinical trial for rare disease pill succeeds, but still proves disappointing

By Adam Feuerstein

Health

Watch: How did the amyloid hypothesis go from promising to perilous in the search for Alzheimer’s treatments?

By Damian Garde and Alex Hogan

Biotech

MIT-owned lab buildings in Kendall Square change hands for reported $1.1 billion

By Tim Logan

Biotech

Startup Spotlight: Flagship’s latest single-cell sequencing startup gets a name: Cellarity

By Kate Sheridan

Biotech

You have questions on CRISPR. We have answers

By Sharon Begley and Adam Feuerstein

Biotech

After forced sale, PatientsLikeMe founder frets that U.S. policy could chill collaboration in biotech

By Matthew Herper

Biotech

Apps are promising to match cancer patients to clinical trials. An ethicist digs into what could go wrong

By Damian Garde and Rebecca Robbins

The Readout LOUD

Listen: Drug pricing partisanship, tech’s march into health care, and Tinder for clinical trials

By Damian Garde and Rebecca Robbins

Biotech

As more dogs are tested for potential genetic diseases, experts say use caution

By Jonathan Saltzman — Boston Globe

Biotech

Shaped like a tennis ball, this cancer protein was thought ‘undruggable.’ Amgen found a way to target it

By Adam Feuerstein

Biotech

Vertex to pay startup Kymera $70 million in R&D deal

By Jonathan Saltzman — Boston Globe

Biotech

Webinar: The race to deliver CRISPR

By Sharon Begley and Adam Feuerstein

Biotech

Myovant’s uterine fibroid drug worked in Phase 3. Now comes competition

By Damian Garde

Biotech

How a biotech executive seizes on big ideas, from anti-aging therapies to antibiotics

By Matthew Herper

Biotech

Grail, the liquid biopsy startup, picks an approach for its cancer test

By Matthew Herper

Biotech

ElevateBio launches to help other cell, gene therapy companies lift off

By Kate Sheridan

Politics

FDA finalizes rules for when a biosimilar is ‘interchangeable’ with a biologic

By Nicholas Florko and Ed Silverman

Biotech

French drug maker Servier sets up U.S. headquarters in Boston’s Seaport

By Jonathan Saltzman — Boston Globe

Adam's Take

Fibrogen’s obtuse disclosures about anemia pill raise concerns over heart safety, putting approval at risk

By Adam Feuerstein

Biotech

Something Ventured: Casma Therapeutics and four other startups got venture funding a year ago. Did it help them do what they said it would?

By Kate Sheridan

The Readout LOUD

Listen: Pharma felonies, cardiac CRISPR, and a strange day at the FDA

By Damian Garde and Adam Feuerstein

Biotech

Gene therapies are a hard sell. Bluebird hopes to do better in Europe

By Adam Feuerstein

Biotech

‘It is a bit uncomfortable’: Before the criminal allegations, an awards program honored Insys and Theranos

By Rebecca Robbins

‘I was a 31-year-old kid in a way’: How a cancer diagnosis changed a health care reporter

Novartis CEO coy about pricing its gene therapy for spinal muscular atrophy

Microbiome therapies could be the next frontier in medicine. But how exactly do you make them?

Tocagen continues a brain cancer gene therapy clinical trial. Investors fear the worst

Four of the world’s largest drug companies are teaming with Verily. Here is what they get

Singapore digital health startup raises $35 million, plans headquarters move to Boston

Biocryst clinical trial for rare disease pill succeeds, but still proves disappointing

Watch: How did the amyloid hypothesis go from promising to perilous in the search for Alzheimer’s treatments?

MIT-owned lab buildings in Kendall Square change hands for reported $1.1 billion

Startup Spotlight: Flagship’s latest single-cell sequencing startup gets a name: Cellarity

You have questions on CRISPR. We have answers

After forced sale, PatientsLikeMe founder frets that U.S. policy could chill collaboration in biotech

Apps are promising to match cancer patients to clinical trials. An ethicist digs into what could go wrong

Listen: Drug pricing partisanship, tech’s march into health care, and Tinder for clinical trials

As more dogs are tested for potential genetic diseases, experts say use caution

Shaped like a tennis ball, this cancer protein was thought ‘undruggable.’ Amgen found a way to target it

Vertex to pay startup Kymera $70 million in R&D deal

Webinar: The race to deliver CRISPR

Myovant’s uterine fibroid drug worked in Phase 3. Now comes competition

How a biotech executive seizes on big ideas, from anti-aging therapies to antibiotics

Grail, the liquid biopsy startup, picks an approach for its cancer test

ElevateBio launches to help other cell, gene therapy companies lift off

FDA finalizes rules for when a biosimilar is ‘interchangeable’ with a biologic

French drug maker Servier sets up U.S. headquarters in Boston’s Seaport

Fibrogen’s obtuse disclosures about anemia pill raise concerns over heart safety, putting approval at risk

Something Ventured: Casma Therapeutics and four other startups got venture funding a year ago. Did it help them do what they said it would?

Listen: Pharma felonies, cardiac CRISPR, and a strange day at the FDA

Gene therapies are a hard sell. Bluebird hopes to do better in Europe

‘It is a bit uncomfortable’: Before the criminal allegations, an awards program honored Insys and Theranos

Biotech

Sign up for our Daily Recap newsletter